Q3 Revenue Climbs to $37.7M as Net Loss Narrows and SG&A Drops 42%
SPRY is trading near its 52-week low of $2.59 (2.3% above the low).
Summary
ARS Pharma posted Q3 2026 total revenue of $37.7 million, up from $32.5 million a year ago, with neffy U.S. net product revenue of $33.4 million versus $31.3 million. The net loss narrowed to $35.6 million, or $(0.36) per share, from $51.2 million a year earlier, and SG&A fell to $43.5 million from $74.8 million after the company killed linear TV and broad consumer advertising — a 42% reduction from the first-half 2026 quarterly average. neffy's total U.S. market share reached 5% (up from 4%) and about 9% in field-targeted accounts, which the company says represent roughly 44% of the market opportunity. Cash stood at $138.4 million as of September 30, and management reaffirmed its path to cash flow breakeven by the end of 2027. The stock sits near its 52-week low, so the cost discipline and narrowed loss are the key items; ARS-2 interim Phase 2b data in Q1 2027 is the next scheduled readout.
At the time of this announcement, SPRY was trading at $2.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $263.5M. The 52-week trading range was $2.59 to $13.15. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.